Recent News

• 08.06.2026 - Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
• 07.27.2026 - Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
• 07.09.2026 - Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
• 06.18.2026 - Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
• 05.21.2026 - Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
• 05.07.2026 - Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
• 04.03.2026 - Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
• 03.25.2026 - Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
• 02.26.2026 - Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
• 02.05.2026 - Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Recent Filings

• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1
• 08.04.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.28.2026 - 8-K Current report
• 07.08.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 06.18.2026 - EX-99.1 EX-99.1
• 06.18.2026 - 8-K Current report
• 06.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.05.2026 - 4 Statement of changes in beneficial ownership of securities